X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the termination, Jounce Therapeutics will not merge with Redx. The business combination was supposed to aim the development of RXC007, a next-generation selective ROCK2 inhibitor, which is currently being assessed in a Phase 2a study in idiopathic pulmonary fibrosis.
Lead Product(s): RXC007
Therapeutic Area: Oncology Product Name: RXC007
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Redx Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination April 03, 2023
Details:
Through the merger agreement, Jounce Therapeutics will expand its oncology pipeline by adding JTX-2011 (vopratelimab), JTX-8064 and pimivalimab to its portfolio.
Lead Product(s): Vopratelimab,JTX-4014
Therapeutic Area: Oncology Product Name: JTX-2011
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Concentra Biosciences
Deal Size: $96.4 million Upfront Cash: $96.4 million
Deal Type: Acquisition March 27, 2023
Details:
JTX-8064 is a human IgG4 mAb designed to specifically bind to the macrophage receptor Leukocyte Immunoglobulin Like Receptor B2, inhibiting LILRB2 binding with its ligands which may result in reprogramming immune-suppressive macrophages to enhance anti-tumor immunity.
Lead Product(s): JTX-8064,Pimivalimab
Therapeutic Area: Oncology Product Name: JTX-8064
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
Through the business combination, the combined group's priority will be the development of RXC007, a next-generation selective ROCK2 inhibitor, which is currently being assessed in a Phase 2a study in idiopathic pulmonary fibrosis (IPF).
Lead Product(s): RXC007
Therapeutic Area: Oncology Product Name: RXC007
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Redx Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 23, 2023
Details:
GS-1811, a potentially first-in-class immunotherapy, is designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells in the tumor microenvironment and is in Phase 1 clinical development as a possible treatment for patients with solid tumors.
Lead Product(s): GS-1811,Zimberelimab
Therapeutic Area: Oncology Product Name: GS-1811
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $227.0 million Upfront Cash: $120.0 million
Deal Type: Acquisition December 27, 2022
Details:
JTX-8064 is a highly selective and potent inhibitor of myeloid-specific Leukocyte Immunoglobulin Like Receptor B2 (LILRB2, also known as ILT4) with the potential to reverse PD-(L)1 inhibitor resistance.
Lead Product(s): Pimivalimab,Vopratelimab
Therapeutic Area: Oncology Product Name: JTX-4014
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
JTX-8064, the first tumor-associated macrophage candidate developed from Jounce’s Translational Science Platform, is a humanized IgG4 monoclonal antibody designed to specifically bind to the macrophage receptor Leukocyte Immunoglobulin Like Receptor B2 (LILRB2/ILT4).
Lead Product(s): JTX-8064,Pimivalimab
Therapeutic Area: Oncology Product Name: JTX-8064
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
A Phase 1 clinical trial, named INNATE, of JTX-8064 as a monotherapy and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, is currently enrolling patients with advanced solid tumors.
Lead Product(s): JTX-8064
Therapeutic Area: Oncology Product Name: JTX-8064
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
JTX-1811, which will be referred to as GS-1811 in Gilead’s pipeline, is a monoclonal antibody created by Jounce and designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells.
Lead Product(s): JTX-1811
Therapeutic Area: Oncology Product Name: GS-1811
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $805.0 million Upfront Cash: $85.0 million
Deal Type: Licensing Agreement June 15, 2021
Details:
Two trial in progress posters, on the Phase 1 INNATE clinical trial and the Phase 2 SELECT clinical trial, will be presented at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting being held June 4-8, 2021.
Lead Product(s): JTX-8064,Pembrolizumab
Therapeutic Area: Oncology Product Name: JTX-8064
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
